Cost-effectiveness of immune checkpoint inhibitors in nsclc according to pd-l1 expression

Página do item simplificado
dc.contributor.authorAguiar, Pedro, Jr. [UNIFESP]
dc.contributor.authorPerry, Luke A.
dc.contributor.authorLopes, Gilberto L., Jr.
dc.date.accessioned2019-01-21T10:29:40Z
dc.date.available2019-01-21T10:29:40Z
dc.date.issued2016
dc.description.affiliationOncology & Hematology Department, Clinical Oncology Sector, Federal University of São Paulo, Brazil
dc.description.affiliationMonash School of Medicine, Faculty of Medicine, Nursing & Health Sciences, Melbourne, Australia
dc.description.affiliationSylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
dc.description.affiliationUnifespOncology & Hematology Department, Clinical Oncology Sector, Federal University of São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent119-122
dc.identifierhttp://dx.doi.org/10.2217/lmt-2016-0016
dc.identifier.citationLung Cancer Management. London, v. 5, n. 3, p. 119-122, 2016.
dc.identifier.doi10.2217/lmt-2016-0016
dc.identifier.issn1758-1966
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/49320
dc.identifier.wosWOS:000390431700001
dc.language.isoeng
dc.publisherHindawi Ltd
dc.relation.ispartofLung Cancer Management
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectCost-Effectivenessen
dc.subjectHealth Technology Assessmenten
dc.subjectImmunotherapyen
dc.subjectLung CancerCell Lung-Canceren
dc.subjectPredictive Biomarkeren
dc.subjectMetaanalysisen
dc.subjectNivolumaben
dc.subjectDocetaxelen
dc.subjectOutcomesen
dc.titleCost-effectiveness of immune checkpoint inhibitors in nsclc according to pd-l1 expressionen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Outras produções